Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma.

Touat M, Gratieux J, Condette Auliac S, Sejean K, Aldea S, Savatovsky J, Perkins G, Blons H, Ligon KL, Idbaih A, Hollebecque A, Gimenez-Roqueplo AP, Laurent-Puig P, Sanson M, Villa C, Di Stefano AL.

Neurology. 2018 Sep 11;91(11):523-525. doi: 10.1212/WNL.0000000000006171. Epub 2018 Aug 17. No abstract available.

PMID:
30120137
2.

Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.

Marks AM, Bindra RS, DiLuna ML, Huttner A, Jairam V, Kahle KT, Kieran MW.

Pediatr Blood Cancer. 2018 May;65(5):e26969. doi: 10.1002/pbc.26969. Epub 2018 Jan 30.

PMID:
29380516
3.

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.

Abdel-Wahab O, Klimek VM, Gaskell AA, Viale A, Cheng D, Kim E, Rampal R, Bluth M, Harding JJ, Callahan MK, Merghoub T, Berger MF, Solit DB, Rosen N, Levine RL, Chapman PB.

Cancer Discov. 2014 May;4(5):538-45. doi: 10.1158/2159-8290.CD-13-1038. Epub 2014 Mar 3.

4.

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.

del Bufalo F, Carai A, Figà-Talamanca L, Pettorini B, Mallucci C, Giangaspero F, Antonelli M, Badiali M, Moi L, Bianco G, Cacchione A, Locatelli F, Ferretti E, Mastronuzzi A.

J Transl Med. 2014 Dec 19;12:356. doi: 10.1186/s12967-014-0356-1.

5.

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J.

Lancet Oncol. 2016 Sep;17(9):1248-60. doi: 10.1016/S1470-2045(16)30122-X. Epub 2016 Jul 30.

PMID:
27480103
6.

Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation.

Mey UJM, Renner C, von Moos R.

Hematol Oncol. 2017 Dec;35(4):890-893. doi: 10.1002/hon.2353. Epub 2016 Sep 19.

PMID:
27641727
7.

Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.

Bautista F, Paci A, Minard-Colin V, Dufour C, Grill J, Lacroix L, Varlet P, Valteau-Couanet D, Geoerger B.

Pediatr Blood Cancer. 2014 Jun;61(6):1101-3. doi: 10.1002/pbc.24891. Epub 2013 Dec 3.

PMID:
24375920
8.

Cobimetinib.

Signorelli J, Shah Gandhi A.

Ann Pharmacother. 2017 Feb;51(2):146-153. doi: 10.1177/1060028016672037. Epub 2016 Oct 4. Review.

PMID:
27701080
9.

Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib.

Wongchenko MJ, McArthur GA, Dréno B, Larkin J, Ascierto PA, Sosman J, Andries L, Kockx M, Hurst SD, Caro I, Rooney I, Hegde PS, Molinero L, Yue H, Chang I, Amler L, Yan Y, Ribas A.

Clin Cancer Res. 2017 Sep 1;23(17):5238-5245. doi: 10.1158/1078-0432.CCR-17-0172. Epub 2017 May 23.

10.

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A.

N Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29.

11.

Vemurafenib and cobimetinib in BRAF-mutated melanoma.

Rahman A.

Lancet Oncol. 2014 Nov;15(12):e535. Epub 2014 Oct 10. No abstract available.

PMID:
25602110
12.

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.

Sullivan RJ, Hamid O, Gonzalez R, Infante JR, Patel MR, Hodi FS, Lewis KD, Tawbi HA, Hernandez G, Wongchenko MJ, Chang Y, Roberts L, Ballinger M, Yan Y, Cha E, Hwu P.

Nat Med. 2019 Jun;25(6):929-935. doi: 10.1038/s41591-019-0474-7. Epub 2019 Jun 6.

PMID:
31171876
13.

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA.

Lancet Oncol. 2014 Aug;15(9):954-65. doi: 10.1016/S1470-2045(14)70301-8. Epub 2014 Jul 15. Erratum in: Lancet Oncol. 2014 Sep;15(10):417.

PMID:
25037139
14.

Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.

Kawaguchi K, Murakami T, Chmielowski B, Igarashi K, Kiyuna T, Unno M, Nelson SD, Russell TA, Dry SM, Li Y, Eilber FC, Hoffman RM.

Oncotarget. 2016 Nov 1;7(44):71737-71743. doi: 10.18632/oncotarget.12328.

15.

Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.

Keating GM.

Drugs. 2016 Apr;76(5):605-15. doi: 10.1007/s40265-016-0562-7. Review.

PMID:
26984388
16.

Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival.

Indini A, Tondini CA, Mandalà M.

Future Oncol. 2019 Mar;15(9):967-977. doi: 10.2217/fon-2018-0659. Epub 2019 Jan 14. Review.

PMID:
30638071
17.

Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib.

van Tilburg CM, Selt F, Sahm F, Bächli H, Pfister SM, Witt O, Milde T.

Pediatr Blood Cancer. 2018 Mar;65(3). doi: 10.1002/pbc.26893. Epub 2017 Dec 12.

PMID:
29230924
18.

Recurrent ganglioglioma in adults treated with BRAF inhibitors.

Chamberlain MC.

CNS Oncol. 2016;5(1):27-9. doi: 10.2217/cns.15.40. Epub 2015 Dec 18.

19.

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.

de la Cruz-Merino L, Di Guardo L, Grob JJ, Venosa A, Larkin J, McArthur GA, Ribas A, Ascierto PA, Evans JTR, Gomez-Escobar A, Barteselli G, Eng S, Hsu JJ, Uyei A, Dréno B.

J Transl Med. 2017 Jun 24;15(1):146. doi: 10.1186/s12967-017-1246-0.

20.

The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.

Amaral T, Nouri N, Garbe C.

Expert Rev Anticancer Ther. 2016 Jul;16(7):705-15. doi: 10.1080/14737140.2016.1192469. Epub 2016 Jun 10. Review.

PMID:
27219630

Supplemental Content

Support Center